keyword
Keywords Inflammatory bowel disease, tn...

Inflammatory bowel disease, tnf, adalimumab

https://read.qxmd.com/read/38068547/what-should-we-know-about-drug-levels-and-therapeutic-drug-monitoring-during-pregnancy-and-breastfeeding-in-inflammatory-bowel-disease-under-biologic-therapy
#21
REVIEW
Mathilde Barrau, Xavier Roblin, Leslie Andromaque, Aurore Rozieres, Mathias Faure, Stéphane Paul, Stéphane Nancey
Data on the real long-term influences of in utero drug exposure in pregnant women on childhood development are scarce and remain not well determined and depend on the duration of in utero drug exposure and maternal drug levels. Therapeutic drug monitoring (TDM) during pregnancy may help limit fetal drug exposure while maintaining an effective dose for the treatment of the underlying inflammatory bowel disease (IBD) in women. Most antibody therapies used in patients with IBD are IgG molecules which are actively transported across the placenta, especially during the third trimester of the pregnancy...
December 4, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/38041850/biologic-therapy-for-inflammatory-bowel-disease-real-world-comparative-effectiveness-and-impact-of-drug-sequencing-in-13-222-patients-within-the-uk-ibd-bioresource
#22
JOURNAL ARTICLE
Christina Kapizioni, Rofaida Desoki, Danielle Lam, Karthiha Balendran, Eman Al-Sulais, Sreedhar Subramanian, Joanna E Rimmer, Juan De La Revilla Negro, Holly Pavey, Laetitia Pele, Johanne Brooks, Gordon W Moran, Peter M Irving, Jimmy K Limdi, Christopher A Lamb, Miles Parkes, Tim Raine
BACKGROUND AND AIMS: To compare effectiveness of different biologic therapies and sequences in patients with Inflammatory Bowel Disease (IBD) using real-world data from a large cohort with long exposure. METHODS: Demographic, disease, treatment and outcome data were retrieved for patients in the UK IBD BioResource. Effectiveness of treatment was based on persistence free of discontinuation or failure, analysed by Kaplan-Meier survival analysis with inverse probability of treatment weighting to adjust for differences between groups...
December 2, 2023: Journal of Crohn's & Colitis
https://read.qxmd.com/read/38028955/dose-escalation-of-biologics-in-biologic-na%C3%A3-ve-patients-with-ulcerative-colitis-outcomes-from-the-odessa-uc-study
#23
JOURNAL ARTICLE
Sabyasachi Ghosh, Niranjan Kathe, Kandavadivu Umashankar, Kirti Mirchandani, Arunima Hait, Riyanka Paul, Ninfa Candela, Tao Fan
BACKGROUND: Dose escalation of biologics may regain treatment response in patients with ulcerative colitis (UC). However, dose escalation rates and associated outcomes and costs are not well characterized in biologic-naïve patients receiving antitumor necrosis factor-alpha (anti-TNF-α) treatments, such as infliximab or adalimumab or vedolizumab. METHODS: ODESSA-UC, a retrospective cohort study investigating dose escalation in patients with UC who had received first-line biologics, used data from IBM MarketScan databases...
October 2023: Crohn's & colitis 360
https://read.qxmd.com/read/38025596/correlation-of-anti-tnf-a-biological-therapy-with-periodontal-conditions-and-osteonecrosis-in-autoimmune-patients-a-systematic-review
#24
REVIEW
Rana Majdi Abunemer, Rakan Saifuddin Shaheen, Renad Abudullah Alghamdi
OBJECTIVES: This systematic review aims to investigate the impact of tumor necrotic factor alpha inhibitors in suppressing bone resorption in periodontitis, and its potential to cause osteonecrosis. Extensive electronic research was conducted following the PRISMA guidelines, which connected various aspects of anti-TNF-a (anti-tumor necrosis factor-a) to periodontitis and osteonecrosis patients. BACKGROUND: TNF-a inhibitors are broadly indicated in the treatment of autoimmune patients with possible joint resorption and increased inflammatory processes such as rheumatoid arthritis and inflammatory bowel disease, where they reduce bone loss and certain mediators...
November 2023: Saudi Dental Journal
https://read.qxmd.com/read/38025145/retrospective-assessment-of-an-adalimumab-model-informed-precision-dosing-support-tool-for-use-in-pediatric-inflammatory-bowel-disease
#25
JOURNAL ARTICLE
Yesenia Avalos, M David Gothard, Jonathan Moses, Michael Finkler
OBJECTIVES: Therapeutic drug monitoring in pediatric inflammatory bowel disease (IBD) has been used to achieve and maintain remission. Few guidelines exist to aid clinicians in the adjustment of anti-tumor necrosis factor therapies. The objective was to assess the agreement between real-world postinduction and posteriori analysis of retrospective data, using 2 novel pharmacokinetic (PK) models for adalimumab. METHODS: A retrospective chart review was conducted in pediatric IBD patients treated with adalimumab...
2023: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://read.qxmd.com/read/37977286/polymersomes-for-protein-drug-delivery-across-intestinal-mucosa
#26
JOURNAL ARTICLE
Jorge Javier Muso-Cachumba, Sa Feng, Mona Belaid, Yunyue Zhang, Carlota de Oliveira Rangel-Yagui, Driton Vllasaliu
The oral administration is the route preferred by patients due to its multiple advantages. In the case of biopharmaceuticals, due to their low stability and absorption in the intestine, these molecules must be administered by injectable routes. To circumvent these problems, several strategies have been studied, among which the use of nanosystems, such as polymersomes, can be highlighted. In this work the potential of poloxamer 401 polymersomes as a system for oral delivery of antibodies was evaluated. IgG-FITC-loaded poloxamer 401 polymerosomes were initially used to assess whether it improves intestinal epithelial permeation in Caco-2 cell monolayers...
November 15, 2023: International Journal of Pharmaceutics
https://read.qxmd.com/read/37961895/anti-drug-antibodies-against-anti-tnf-in-patients-with-inflammatory-bowel-disease-an-evaluation-of-possible-strategies
#27
JOURNAL ARTICLE
Suzanne I Anjie, Jurij Hanzel, Krisztina B Gecse, Geert R D'Haens, Johannan F Brandse
OBJECTIVE: Immunogenicity against anti-TNF antibodies usually leads to loss of response. We aimed to evaluate the efficacy of clinical strategies to improve clinical remission and pharmacokinetics upon detection of anti-drug antibodies (ADA). METHODS: Inflammatory bowel disease (IBD) patients with ADA against infliximab or adalimumab were identified through a single centre database search covering 2004-2022. Criteria for successful intervention upon ADA detection (baseline) were clinical remission after 1 year without further change in strategy...
November 14, 2023: Scandinavian Journal of Gastroenterology
https://read.qxmd.com/read/37959304/efficacy-and-safety-of-adalimumab-biosimilar-gp2017-in-patients-with-inflammatory-bowel-disease
#28
JOURNAL ARTICLE
Marta Vernero, Cristina Bezzio, Davide G Ribaldone, Stefania Costa, Davide Scalvini, Elisa Tribocco, Gianpiero Manes, Simone Saibeni
(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF agents used for inflammatory bowel disease (IBD). To date, there is little real-world data about the use of GP2017 in IBD patients. The aim of our study was to evaluate the effectiveness and safety of this biosimilar in an IBD population. (2) Methods: This is an observational retrospective study including patients that were all treated with GP2017 as a first step or as a switch from the originator or other biosimilars. The clinical activity was evaluated at baseline and after 6 and 12 months of therapy...
October 29, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37943286/de-escalation-of-biological-treatment-in-inflammatory-bowel-disease-a-comprehensive-review
#29
JOURNAL ARTICLE
Javier P Gisbert, María Chaparro
INTRODUCTION: Biological therapy is an effective treatment for inflammatory bowel disease (IBD). However, due to cost and safety concerns, after achieving remission, dose de-escalation strategies have been suggested. AIM: To critically review available data on dose de-escalation of biologics (or other advanced therapies) in IBD. We will focus on studies evaluating de-escalation to standard dosing in patients initially optimised, and also on studies assessing de-escalation from standard dosing...
November 1, 2023: Journal of Crohn's & Colitis
https://read.qxmd.com/read/37921344/real-world-persistence-of-successive-biologics-in-patients-with-inflammatory-bowel-disease-findings-from-rotary
#30
JOURNAL ARTICLE
Noa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, Tim Bancroft, Ninfa Candela, Tao Fan, Kandavadivu Umashankar, David T Rubin
BACKGROUND: Patients with inflammatory bowel disease (IBD) may receive multiple successive biologic treatments in clinical practice; however, data are limited on the comparative effectiveness of biologics and the impact of treatment sequence on outcomes. METHODS: The ROTARY (Real wOrld ouTcomes Across tReatment sequences in inflammatorY bowel disease patients) study was a retrospective, observational cohort study conducted using data from the Optum Clinical Database between January 1, 2012, and February 29, 2020...
October 31, 2023: Inflammatory Bowel Diseases
https://read.qxmd.com/read/37908975/efficacy-and-safety-of-adalimumab-biosimilar-hs016-in-inflammatory-bowel-disease-from-the-real-world-study
#31
JOURNAL ARTICLE
Fang Wang, Xiaofei Li, Yanting Shi, He Zhou, Gang Yang, Ruixia Li, Tong Wu, Jie Liang
Objective: Adalimumab (ADA) is an effective treatment for inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn's disease (CD). The equal effect between the original ADA and biosimilars from Europe and the United States has been shown. However, the biosimilar of ADA is different in China. The effectiveness and safety data of ADA biosimilar (HS016) in China have yet to be discovered. Patients and methods: 91 patients (75 CD, 16 UC) received HS016 treatment and were enrolled in this study. Therapeutic response and safety profiles were analyzed...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37900586/dose-escalation-of-adalimumab-as-a-strategy-to-overcome-anti-drug-antibodies-a-case-report-of-infantile-onset-inflammatory-bowel-disease
#32
Silvana Ancona, Sara Signa, Chiara Longo, Giuliana Cangemi, Roberta Carfora, Enrico Drago, Alessandro La Rosa, Marco Crocco, Andrea Chiaro, Paolo Gandullia, Serena Arrigo
BACKGROUND: Treatment of infantile-onset inflammatory bowel disease (IO-IBD) is often challenging due to its aggressive disease course and failure of standard therapies with a need for biologics. Secondary loss of response is frequently caused by the production of anti-drug antibodies, a well-known problem in IBD patients on biologic treatment. We present a case of IO-IBD treated with therapeutic drug monitoring (TDM)-guided high-dose anti-tumor necrosis factor therapy, in which dose escalation monitoring was used as a strategy to overcome anti-drug antibodies...
October 14, 2023: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/37885792/molecular-docking-analysis-of-natural-compounds-as-tnf-%C3%AE-inhibitors-for-crohn-s-disease-management
#33
JOURNAL ARTICLE
Mamdoh S Moawadh
Crohn's disease (CD) is a type of inflammatory bowel disease that is immune-mediated and affects the gastrointestinal tract. The chronic and severe nature of this condition leads to diminished health-related life quality, and frequent hospitalization. While medications such as sulfasalazine, corticosteroids, and immuno-suppressants are used to manage the condition, there are no definite treatments for pain and inflammation associated with CD. TNF-α is a prominent target, and medicines such as infliximab and adalimumab have pharmacological efficacy; however, they also have significant toxicity...
2023: Bioinformation
https://read.qxmd.com/read/37847820/efficacy-and-safety-of-anti-tumor-necrosis-factor-alpha-in-very-early-onset-inflammatory-bowel-disease
#34
JOURNAL ARTICLE
Lauren V Collen, Vanessa Mitsialis, David Y Kim, Mairead Bresnahan, Jessica Yang, Margaret Tuthill, Abigail Combs, Jared Barends, Michael Field, Enju Liu, Richelle Bearup, Ibeawuchi Okoroafor, Christoph Klein, Aleixo M Muise, Athos Bousvaros, Jodie Ouahed, Scott B Snapper
BACKGROUND: Very early onset inflammatory bowel disease (VEOIBD) is defined as disease onset in patients younger than 6 years. Challenges in treatment of VEOIBD include lack of approved therapies and increased incidence of monogenic immunodeficiencies. We report on patterns of anti-TNF use, efficacy, and safety in a large cohort of patients with VEOIBD. METHODS: Very early onset inflammatory bowel disease patients receiving care at a single center were prospectively enrolled in a data registry and biorepository starting in 2012...
October 17, 2023: Inflammatory Bowel Diseases
https://read.qxmd.com/read/37823516/validation-of-the-pharmacokinetic-model-for-anti-tnf%C3%AE-clearance-in-infants-exposed-to-anti-tnf%C3%AE-during-pregnancy
#35
JOURNAL ARTICLE
Jantien W Wieringa, Matthijs D Kruizinga, Gertjan J A Driessen, C Janneke van der Woude, Mette Julsgaard
BACKGROUND AND AIMS: ECCO guideline recommend postponing live attenuated vaccines in infants exposed to anti-Tumor Necrosis Factor alpha (anti-TNFα) in utero until drug clearance. The aim was to validate the predictive performance of the anti-TNFα clearance model. METHODS: Newborns and anti-TNFα concentrations from the prospective PETIT cohort were included. The anti-TNFα clearance model was used to predict all measured concentrations in the PETIT cohort, based on the measured cord blood concentration and the mean population clearance described in the model...
October 12, 2023: Journal of Crohn's & Colitis
https://read.qxmd.com/read/37801628/baseline-trem-1-whole-blood-gene-expression-does-not-predict-response-to-adalimumab-treatment-in-patients-with-ulcerative-colitis-or-crohn-s-disease-in-the-serene-studies
#36
JOURNAL ARTICLE
Bram Verstockt, Valerie Pivorunas, Naim Al Mahi, Nizar Smaoui, Heath Guay, Nicholas A Kennedy, James R Goodhand, Simeng Lin, Benjamin Y H Bai, Stephen B Hanauer, Marc Ferrante, Julian Panés, Séverine Vermeire
BACKGROUND AND AIMS: This study assessed whether baseline triggering receptor expressed on myeloid cells [TREM-1] whole blood gene expression predicts response to anti-TNF therapy in patients with UC or CD. METHODS: TREM-1 whole blood gene expression was analysed by RNA sequencing [RNA-seq] in patients with moderately to severely active UC or CD treated with adalimumab in the Phase 3 SERENE-UC and SERENE-CD clinical trials. The predictive value of baseline TREM-1 expression was evaluated and compared according to endoscopic and clinical response vs non-response, and remission vs non-remission, at Weeks 8 and 52 [SERENE-UC], and Weeks 12 and 56 [SERENE-CD]...
October 6, 2023: Journal of Crohn's & Colitis
https://read.qxmd.com/read/37788929/comparing-persistence-of-new-biologics-to-conventional-anti-tnf-alphas-in-adult-patients-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis-protocol
#37
JOURNAL ARTICLE
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W Leong
BACKGROUND: Biological therapy is a cornerstone of managing moderate-to-severe inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD). New biologics have been evolving over the past 20 years and selection of an agent remains challenging.Drug persistence measures the duration of time from initiation to discontinuation of a therapy, which can be a surrogate marker of drug tolerance and efficacy. OBJECTIVES: The study aimed to compare drug persistence of new generation biologics for the treatment of UC and CD (vedolizumab, ustekinumab, certolizumab, tofacitinib, natalizumab and golimumab) with conventional anti-tumor necroisis factor alphas (anti-TNF alphas) (adalimumab and infliximab) in adult patients with IBD...
October 3, 2023: BMJ Open
https://read.qxmd.com/read/37787642/adalimumab-versus-infliximab-in-luminal-pediatric-crohn-s-disease-comparable-outcomes-in-a-prospective-multicenter-cohort-study
#38
JOURNAL ARTICLE
Jennifer C deBruyn, Hien Q Huynh, Anne M Griffiths, Kevan Jacobson, David Mack, Colette Deslandres, Wael El-Matary, Anthony R Otley, Peter C Church, Sally Lawrence, Eytan Wine, Mary Sherlock, Jeffrey Critch, Eric I Benchimol, Prévost Jantchou, Mohsin Rashid, Matthew W Carroll, Kevin Bax, Amanda Ricciuto, Nicholas Carman, Thomas D Walters, Eileen Crowley
BACKGROUND: This study compared real-world effectiveness between adalimumab (ADA) and infliximab (IFX) in children with Crohn's disease (CD). METHODS: Children enrolled into the prospective Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN) National Inception Cohort between 2014 and 2020 who commenced ADA or IFX as first anti-tumor necrosis factor (antiTNF) agent for luminal CD were included. Multivariate logistic regression modelled the propensity of commencing ADA; propensity score matching was used to match IFX-treated children to ADA-treated children...
October 3, 2023: American Journal of Gastroenterology
https://read.qxmd.com/read/37776235/baseline-expression-of-immune-gene-modules-in-blood-is-associated-with-primary-response-to-anti-tnf-therapy-in-crohn-s-disease-patients
#39
JOURNAL ARTICLE
Benjamin Y H Bai, Mark Reppell, Nizar Smaoui, Jeffrey F Waring, Valerie Pivorunas, Heath Guay, Simeng Lin, Neil Chanchlani, Claire Bewshea, James R Goodhand, Nicholas A Kennedy, Tariq Ahmad, Carl A Anderson
BACKGROUND AND AIMS: Anti-TNF therapy is widely used for treatment of inflammatory bowel disease, yet many patients are primary non-responders, failing to respond to induction therapy. We aimed to identify blood gene expression differences between primary responders and primary non-responders to anti-TNF monoclonal antibodies (infliximab and adalimumab); and to predict response status from blood gene expression and clinical data. METHODS: The Personalised Anti-TNF Therapy in Crohn's Disease (PANTS) study is a UK-wide prospective observational cohort study of anti-TNF therapy outcome in anti-TNF naive Crohn's disease patients (ClinicalTrials...
September 30, 2023: Journal of Crohn's & Colitis
https://read.qxmd.com/read/37766088/humoral-immunity-in-immunosuppressed-ibd-patients-after-the-third-sars-cov-2-vaccination-a-comparison-with-healthy-control-subjects
#40
JOURNAL ARTICLE
Richard Vollenberg, Eva Ulla Lorentzen, Joachim Kühn, Tobias Max Nowacki, Jörn Arne Meier, Jonel Trebicka, Phil-Robin Tepasse
INTRODUCTION: The COVID-19 pandemic is a result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccination against COVID-19 is crucial for preventing severe illness and controlling the pandemic. This study aimed to examine how immunosuppressed patients with inflammatory bowel disease (IBD) responded to the third mRNA vaccination against SARS-CoV-2. The patients were undergoing treatments such as anti-TNF (infliximab, adalimumab), anti-α4ß7 integrin (vedolizumab), anti-IL12/23 (ustekinumab) and azathioprine (purine analog)...
August 24, 2023: Vaccines
keyword
keyword
24901
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.